Viral immunity and vaccination (viva) human immunology project consortium (hipc)
Active Cooperative Agreement Awarded Last action
- Award ID
- U19AI168631
- Recipient
-
Icahn School Of Medicine At Mount Sinai UEI C8H9CNG1VBD9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $27,762,186
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 93% complete
- Place of performance
- New York, NY 10029, USA
Award details come from USAspending.gov.
Description
- Abstract
- The viral immunity and vaccination (viva) human immunology project consortium (hipc) will carry out a comprehensive systems immunology program to assess the dynamic human immune response to sars-COV- 2, seasonal influenza viruses and tetravalent and trivalent dengue vaccines and subsequent infections by those pathogens. IT will generate comprehensive innate, cellular and adaptive immune signatures that correlate with vaccine outcomes. The viva hipc will leverage recent advances in human immune profiling methods to characterize the diverse states of the human immune system before and after vaccination against these viral pathogens of great public health concern using novel immune phenotyping and genomics strategies that generate data and tools to be used for downstream data analysis and functional investigations. The proposed studies will use longitudinal biospecimens from established human cohorts of respiratory infections and vaccinations in the US and argentina as well as from vaccine trials in the US (provided by the clinical core, core b). In addition, validation experiments using human tonsils sourced from healthy individuals and exposed EX vivo to the different vaccine types will be conducted. Three complementary, well-integrated projects will produce in-depth human immune profiles and signatures of sars-COV-2 vaccinations and infections (project 1), seasonal influenza vaccinations and infections (project 2) as well as dengue vaccine and human challenge studies (project 3). Unique in our approach is the use of longitudinal cohorts for in vivo profiling, supported by EX vivo human tonsillar histoculture (HC) models for infection and vaccination. Our holistic approach will provide cutting- responses to vaccinations and infections by the immune phenotyping core (core c), genomics/transcriptomics, including scrnaseq, citeseq and spatial tissue transcriptomics by the genomics core (core d), and experimental vaccinations in primary human tonsillar histocultures (HC) in projects 1, 2 and 3. Data mining, bioinformatics to identify the network components and infer their interactions and correlations important for vaccine outcomes will be done by the data management and analysis core (core e). The viva hipc will make the data, analyses and immune profiles generated available to the scientific community by coupling our local data infrastructure to immport (directly or through the hipc coordinating center). This integration will ensure full and timely release of clinical, sample, and experimental metadata in synchrony with genomic data releases to standard data repositories including SRA, GEO, and genbank (core e). The viva team (DRS. Krammer, garcia-sastre, durbin, gamarnik, van bakel and sebra) led by DR. Fernandez-sesma and DR. Simon includes physicians, physician scientists and scientists with complementary expertise in viral immunology, viral pathogenesis, vaccinology, genomics, data analysis and a proven track record of collaboration and excellence.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $2,265,730 | |
| Amendment | $2,265,730 | |
| Amendment | $2,265,730 | |
| Amendment | $400,000 | |
| Amendment | $399,999 | |
| Amendment | $226,573 | |
| Amendment | $226,573 | |
| Amendment | $2,039,157 | |
| Amendment | $2,039,157 | |
| Amendment | $2,039,157 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $2,265,730 | |
| Amendment | $2,265,730 | |
| Amendment | $2,265,730 | |
| Amendment | $2,265,730 | |
| Amendment | $2,265,730 | |
| Original award | $2,265,730 |
Show all 23
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Fundacion Instituto Leloir | $69,066 | |
| Fundacion Instituto Leloir | $126,688 | |
| Fundacion Instituto Leloir | $170,203 | |
| Fundacion Instituto Leloir | $88,336 | |
| The Johns Hopkins University | $171,572 | |
| The Johns Hopkins University | $122,558 |
Quick answers
Who received award U19AI168631?
U19AI168631 was awarded to Icahn School Of Medicine At Mount Sinai by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 22, 2022.
How much is award U19AI168631 worth?
$27,762,186 has been obligated on U19AI168631.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award